Fig. 2: Pharmacokinetics profiles following the first intramuscular administration of GX-I7 ranging from 60 to 1700 μg/kg. | British Journal of Cancer

Fig. 2: Pharmacokinetics profiles following the first intramuscular administration of GX-I7 ranging from 60 to 1700 μg/kg.

From: GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8+/CD4+ T cells and TILs in patients with locally advanced or metastatic solid tumours

Fig. 2

a The mean serum concentration-time profiles of GX-I7, b the maximum concentration (Cmax) versus dose of GX-I7, and C the area under the serum concentration-time curve from time zero to the last measurable time-point (AUClast) versus dose of GX-I7. The results are presented as mean ± standard deviation (SD).

Back to article page